Although we demonstrated that SS18-SSX silencing reduced the susceptibility of ABBV-075 and that the BCL2-related apoptotic pathway is a potential pathway affecting susceptibility, BCLxL is possibly more critical than BCL2 in ABBV-075 treatment for SS. Here, SSX2 is linked to synovial sarcoma.